Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Are Emerging Markets Part Of Big Pharma's Core Business?

Jun 09 2011

• By PharmAsia News

Related Content

Freed From Pfizer, Capsugel May Find More Market Opportunities

Apr 11 2011

Bristol's Focused BioPharma Strategy Starts To Pay Off

Apr 11 2011

Consumer Division Divestments Would Spotlight Firms’ Value – Analysts

Jun 06 2011

In R&D Shakeup, Pfizer Tries New Outsourcing Model

May 26 2011

Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says

May 03 2011

With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market

Oct 18 2010

BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)

May 06 2011

Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent

Apr 13 2009

Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical

May 24 2010

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

Mar 07 2011

Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields

Mar 08 2011

Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun

Jun 02 2011

Listing Of MNC Arms In India Has Been Rough Ride With Stray Sparks Of Hope

Jun 09 2011

Bristol’s Nutritionals Business Spins Out; IPO Well-Received By Investors

Feb 11 2009

More from Archive

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window